[go: up one dir, main page]

CN1328819A - Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process - Google Patents

Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process Download PDF

Info

Publication number
CN1328819A
CN1328819A CN01129505A CN01129505A CN1328819A CN 1328819 A CN1328819 A CN 1328819A CN 01129505 A CN01129505 A CN 01129505A CN 01129505 A CN01129505 A CN 01129505A CN 1328819 A CN1328819 A CN 1328819A
Authority
CN
China
Prior art keywords
silver
nano
membrane
antibacterial
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01129505A
Other languages
Chinese (zh)
Inventor
朱红军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CNB011107677A priority Critical patent/CN1179646C/en
Priority to CN01223000U priority patent/CN2479952Y/en
Application filed by Individual filed Critical Individual
Priority to CN01129505A priority patent/CN1328819A/en
Priority to CNB011295074A priority patent/CN1169529C/en
Priority to CNB018231578A priority patent/CN1224479C/en
Priority to PCT/CN2001/001584 priority patent/WO2002090025A1/en
Publication of CN1328819A publication Critical patent/CN1328819A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A61L2/238—Metals or alloys, e.g. oligodynamic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F9/00—Making metallic powder or suspensions thereof
    • B22F9/16—Making metallic powder or suspensions thereof using chemical processes
    • B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
    • B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physics & Mathematics (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A nanometer silver antimicrobial inflammation-reliving film for preventing and curing gynecopathy including bacterial, colpitis and polyinfective mycotica, also preventing and curing gonorrhea and cervicits, etc. is characterized by that it contains pharmaceutically acceptable additive and broad-spectrum antibiotic nanometer silver micropowder, grain size of the nanometer silver is 1-100 nanometers, surface layer is 2-8 nanometers of silver oxide, its core is element siliver, thickness of the film is 10-100 micrometers and nanometer silver content is 5-20 microgram/sq.cm.

Description

Nano silver gynecological disease antibacterial and anti-inflammatory membrane and industrial production process thereof
The invention relates to an antibacterial medicament adopting nano-silver and a production process thereof, in particular to a nano-silver gynecological disease antibacterial anti-inflammatory membrane, an industrial production process thereof and application thereof.
At present, in the treatment of bacterial vaginitis, mycotic vaginitis, mixed infection vaginitis, cervicitis and other diseases of women, a vaginal suppository, a vaginal membrane, vaginal lotion or a vaginal built-in medicine such as an effervescent tablet and the like which are prepared by conventional western medicines, traditional Chinese medicines or compound types are generally applied. Because these drugs have weak antibacterial power and broad antibacterial spectrum, the curative effect is not obvious, the use is inconvenient, patients feel uncomfortable, the clothes and trousers are polluted, and even some drugs have side effects on human bodies, so that the medical field needs to have more updated products for clinical use.
The invention aims to provide a nano-silver gynecological disease antibacterial anti-inflammatory film for treating gynecological diseases.
The second purpose of the invention is to provide an industrial production process of the nano-silver gynecological disease antibacterial anti-inflammatory membrane for treating gynecological diseases.
This and other objects of the invention will be further apparent and elucidated by the following detailed description and description.
The nano-silver gynecological disease antibacterial and anti-inflammatory membrane contains pharmaceutically acceptable additives and anti-aggregation broad-spectrum antibacterial nano-silver micro powder, wherein the particle size of the nano-silver is 1-100 nanometers, the surface layer is 2-8 nanometers of silver oxide, the core is elemental silver, the thickness of the membrane is 10-100 micrometers, and the content of the nano-silver is 5-20 micrograms/cm2(ii) a The pharmaceutically acceptable additives comprise a monomer carrier, a surfactant, a disintegrating agent and a transdermal enhancer.
Further, the nano-silver gynecological disease antibacterial and anti-inflammatory membrane comprises the following components in percentage by weight of 10 kg of pure raw materials:
a: 3 to 4% of polyvinyl alcohol 17-88, 5 to 6% of PVA 25-99,
1 to 2 percent of starch sodium glycolate, 0.1 to 1 percent of nano-silver micro-powder aqueous solution,
0.2-0.5% sodium lauryl sulfate:
b: 8-10% of PVA17-99 aqueous solution;
c: 3-4% nitrocellulose solution.
In the invention, the monomer carrier is a natural high molecular polymer film-forming material and a synthetic high molecular film-forming material, the surfactant is an ionic surfactant or a non-ionic surfactant, the disintegrant is starch and starch derivatives, a cellulose surfactant, an effervescent mixture and glue, the transdermal enhancer is a natural or synthetic polymer and a synthetic elastomer, and the solvent is purified water, alcohol and ether.
The industrial production process of nano silver gynecological disease antibacterial and anti-inflammatory comprises the following steps of preparing the medicine materials and the monomer carrier according to the following proportion:
the medicament formula is as follows (based on 10 kg pure raw material weight):
a: 3 to 4% of polyvinyl alcohol 17-88, 5 to 6% of PVA 25-99,
1 to 2 percent of starch sodium glycolate, 0.1 to 1 percent of nano-silver micro-powder aqueous solution,
0.2-0.5% sodium lauryl sulfate;
b: 8-10% of PVA17-99 aqueous solution;
c: 3-4% nitrocellulose solution.
Then homogenizing, preparing an auxiliary agent, coating for one time, two times and three times, drying, cutting and the like; further, the preparation and homogenization of the medicament and the monomer carrier, the preparation of the auxiliary agent, the three-time film coating in the sequence of B, C, A under the heating condition and the drying until the product is yellow brown yellow.
The nano-silver gynecological disease antibacterial and anti-inflammatory membrane has excellent special performance due to the adoption of the nano-silver, has remarkable antibacterial capacity and wide antibacterial spectrum, has obvious antibacterial functions on gram positive bacteria, gram negative bacteria, fungi and anaerobic bacteria, especially has the same bactericidal capacity on drug-resistant pathogenic bacteria, and has no toxicity, no allergy, no irritation and stronger hydrophilicity-water bactericidal capacity. Therefore, the product of the invention has the advantages of quick effect, good curative effect, convenient use, comfortable body feeling and no toxic or side effect, and is a new generation of nano-grade new product for preventing and treating vaginitis and cervicitis in gynecology.
In the invention, the nano silver micro powder prepared by the nano silver micro powder which is applied by the inventor and has the application number of 01110767.7 and is named as anti-agglomeration broad-spectrum antibacterial nano silver micro powder is adopted.
The broad-spectrum antibacterial nano silver micro powder which is a product disclosed in the patent application No. 01110767.7 of the inventor is adopted as the medicine material of the prostatitis antibacterial and anti-inflammatory gel, and the patent application is incorporated into the reference in the application. The silver particles carried on the micro powder have a particle size of 1-100 nm as detected by a scanning tunnel electron microscope, as shown in figure 4 (figures 1, 2 and 3 in the figures are not treated by an anti-aggregation technology), and the excellent performances of the antibacterial function display of the nano silver micro powder are shown in attached tables 1 and 2
Attached to Table 1, the microorganism is tested in the laboratory of the national liberated military medical testing center.
Attached Table 2, examined by Hill Hospital, Shanghai university of medical, in the bacterial laboratory.
The antibacterial mechanism of the present invention is as follows
From the above, it can be seen that nano-silver replaces-SH group in enzyme living in thallus with-SAg by the most classical antibacterial mechanism, so that enzyme loses activity to cause death of pathogenic bacteria, and the products are enzyme-2 SAg and H2And O, no secondary pathogenic factor exists.
The invention uses the anti-aggregation broad-spectrum antibacterial nano-silver micro-powder as a medicine, and the silver content of the medicine is 0.1-200 mg/g measured according to the methods of United States Pharmacopoeia (USP) and British Pharmacopoeia (BP).
The production process comprises the following auxiliary materials in percentage by weight:
pure water, polyvinyl alcohol, PVA17-88, PVA17-99, sodium starch glycolate, sodium lauryl sulfate, nitrocellulose and the like (the monomer carrier in the process is a natural high polymer film-forming material and a synthetic high polymer film-forming material, and is a conventional additive sold in the market).
The surfactant is ionic surfactant and nonionic surfactant, the disintegrating agent is starch and starch derivatives, cellulose surfactant, effervescent mixture and gum, the skin penetration enhancer is natural and synthetic polymer and synthetic elastomer, and the solvent is purified water, alcohol and ether.
The above adjuvants or additives are commercially available, and further, similar products conventionally used in the industry may be used.
The preparation method comprises uniformly spreading the solution B on a horizontal glass plate, drying at 30-50 deg.C, sequentially uniformly spreading the solution C and the solution A, heating in water bath to completely dry, and cutting into 3 × 4 and 6 × 8 cm pieces.
The thickness of the membrane is 10-100 microns, and the content of nano silver on the membrane is 5-20 micrograms/cm2The thickness of the membrane and the content of the nano-silver micro-powder on the membrane are adjusted by the concentration of the nano-silver micro-powder in the preparation A and the concentration and the dosage of the compounding agent A, B, C.
In the present invention, if necessary, some conventional processing methods can be added, and it is also possible to produce qualified products by omitting one or more steps according to actual conditions, including the conventional knowledge in the field.
Therefore, the nano-silver gynecological disease antibacterial and anti-inflammatory membrane has broad antibacterial spectrum and long-acting property, obvious bacteriostatic ability on pathogenic bacteria with drug resistance, hydrophilicity, stronger bactericidal power when meeting water, and no toxicity, including no accumulative toxicity, no irritation, no allergy and no drug resistance.
The production process flow chart of the invention
The present invention is further illustrated by the following specific examples, which are intended to be illustrative only and not to limit the scope of the invention, wherein all parts and amounts are by weight based on total weight and "M" is molar.
Example 1:
according to application number 01110767.7, the name is: the example is only used for illustration and is not within the protection scope of the claims of the patent application.
The following liquid medicines (calculated according to 10 kg carrier)
A、AgNO3 0.5M，NH3·H2O 0.3M，NaOH 0.1M，
Adding water to the mixture until the total volume is 500 liters;
B. glucose 4M, HNO30.1M, boiling for 1-5 minutes, cooling, adding ethanol to make 10M, and the volume is 50 liters.
Cleaning carrier (medulla Junci), adding 98% medical alcohol and distilled water (ratio of 1: 15), immersing carrier, and vacuum extracting until the carrier is free of organic components and impurities.
Mixing 10 parts and 1 part of B (V/V) uniformly, standing for 10-40 minutes for impregnation, and adding 10 kg of treated carrier (rush). After dipping, pressurizing and homogenizing to mix the liquid medicine and the carrier evenly, adding a dispersant OP-10 continuously (under ventilation condition and proper stirring condition) in the chemical and physical treatment of the mixture in a reaction kettle until the rush is brownish yellow, and then cleaning, drying and crushing the mixture to obtain the aggregation-preventing broad-spectrum antibacterial nano silver micro powder.
Example 2
Based on 10 kg of pure raw material (excluding water and alcohol ether mixture)
Compounding agent:
A. dissolving 4 kg of polyvinyl alcohol (PVA 17-881.6 kg, PVA 25-992.4 kg) in 20L of water, adding 0.8 kg of sodium starch glycolate, stirring uniformly after dissolving, adding 15L of pure water to completely dissolve the sodium starch glycolate, adding 120 g of sodium lauryl sulfate, stirring and dissolving, adding 20 g of nano-silver micropowder prepared according to application No. 01110767.7, and stirring to form a uniformly suspended aqueous solution;
B. 10% PVA17-99 in water;
C. a mixed solution of 4% nitrocellulose in alcohol (1 vol) and ether (2 vol).
The process comprises the following steps:
coating the solution B on a horizontal glass plate, drying at 40 deg.C, sequentially coating the solution C and the solution A, heating in 40 deg.C water bath to dry, and cutting into pieces of 3 × 4 and 6 × 8 cm.
Example 3
Based on 10 kg of pure raw material (excluding water and alcohol ether mixture)
Compounding agent:
A. dissolving 4 kg of polyvinyl alcohol (PVA 17-881.6 kg, PVA 25-992.4 kg) in 20L of water, adding 1 kg of sodium starch glycolate, stirring uniformly, adding 13L of pure water to dissolve completely, adding 120 g of sodium lauryl sulfate, stirring and dissolving, adding 2L of ethanol, stirring uniformly, adding 20 g of nano-silver micropowder prepared according to application No. 01110767.7, and stirring to form a uniformly suspended aqueous solution;
B. 10% PVA17-99 pure water solution;
C. a mixed solution of 4% nitrocellulose in alcohol (1 vol) and ether (2 vol).
The process comprises the following steps:
coating the solution B on a horizontal glass plate, drying at 30 deg.C, sequentially coating the solution C and the solution A, heating in water bath at 30 deg.C to dry, and cutting into pieces of 3 × 4 and 6 × 8 cm.
Example 4
Based on 10 kg of pure raw material (excluding water and alcohol ether mixture)
Compounding agent:
A. dissolving 3.5 kg of polyvinyl alcohol (PVA 17-881.4 kg, PVA 25-992.1 kg) in 20L of water, adding 0.8 kg of sodium starch glycolate, stirring uniformly, adding 13L of pure water to completely dissolve the sodium starch glycolate, adding 120 g of sodium lauryl sulfate, stirring and dissolving, adding 2L of ethanol, stirring uniformly, adding 30 g of nano-silver micropowder, and stirring to obtain a uniformly suspended aqueous solution;
B. 10% PVA17-99 pure water solution;
C. a mixed solution of 4% nitrocellulose in alcohol (1 vol) and ether (2 vol).
The process comprises the following steps:
coating the solution B on a horizontal glass plate uniformly, drying at 35 deg.C, coating the solution C and the solution A in sequence, heating in a water bath at 35 deg.C to dry completely, and cutting into pieces of 3 × 4 and 6 × 8 cm.
Example 5
Based on 10 kg of pure raw material (excluding water and alcohol ether mixture)
Compounding agent:
A. dissolving 3.5 kg of polyvinyl alcohol (PVA 17-881.4 kg, PVA 25-992.1 kg) in 20L of water, adding 1 kg of sodium starch glycolate, stirring uniformly after dissolving, adding 15L of pure water to completely dissolve the sodium starch glycolate, adding 120 g of sodium lauryl sulfate, stirring and dissolving, adding 2L of ethanol, stirring uniformly, adding 30 g of nano-silver micropowder, and stirring to obtain a uniformly suspended aqueous solution;
B. 10% PVA17-99 pure water solution;
C. a mixed solution of 4% nitrocellulose in alcohol (1 vol) and ether (2 vol).
The process comprises the following steps:
coating the solution B on a horizontal glass plate uniformly, drying at 35 deg.C, coating the solution C and the solution A in sequence, heating in a water bath at 35 deg.C to dry completely, and cutting into pieces of 3 × 4 and 6 × 8 cm.
In conclusion, the nano-silver gynecological disease antibacterial and anti-inflammatory membrane has broad-spectrum antibacterial property and long-acting property, has obvious bacteriostatic ability on pathogenic bacteria with drug resistance, has stronger hydrophilicity and water bactericidal ability, and has the advantages of no toxicity (including no accumulative element), no allergy, no drug resistance and the like. The comprehensive performance of the vaginal mucosa membrane is far superior to that of the currently common antibacterial drugs and the drugs prepared from the same silver particles with macroscopic size (micron order), so that the vaginal mucosa membrane is a brand-new and ideal vaginal mucosa membrane special for gynecological disease antibiosis and antiphlogosis, and the precedent that the nanotechnology is used for the application of gynecological infection resistance of human bodies is created.
TABLE 1 inhibition results of PNSM and 8 antibacterial agents
Source of bacterial name PNSM and original control group bacteriostatic diameter (mm) MIC method drug sensitive result of antibacterial drug
Not washed Washing machine 50 times Washing machine 100 times (twice) Negative of To the original Erythromycin Benzoxazole Penicillin Ampicillin Penicillin Cephalosporin Azoline Cephalosporin Furan tablet Cephalosporin Tadin derivatives Qingda (celebration) Mycin Cyclopropan Floxacin hydrate
Staphylococcus aureus ATCC25923 Escherichia coli ATCC25922 Pseudomonas aeruginosa ATCC27853 Clostridium perfringens CMCC (B)64606 Staphylococcus Aureus (MRSA) secretion Staphylococcus Epidermidis (MRSE) secretion Secretion of streptococcus pyogenes Neisseria gonorrhoeae secretion Secretion of Escherichia coli Secretion of enterobacter cloacae Enterobacter aerogenes secretion Secretion of pseudomonas aeruginosa Secretion of stenotrophomonas maltophilia Acinetobacter baumannii secretion Klebsiella pneumoniae secretion Serratia marcescens secretion Secretion of Citrobacter freudenreichii Secretion of Rauverdenum Repentium Hydrophilic aeromonas secretion Aeromonas sobria secretion Vibrio vulnificus secretion Proteus mirabilis secretion Secretion of Proteus vulgaris Proteus pennisatus secretion Candida albicans secretion Candida tropicalis secretion Candida parapsilosis secretion Glomus saccharomycete secretion 18 13 12 10 17 18 9 10 17 9 14 15 14 13 15 16 11 15 13 14 17 11 11 10 21 18 20 27 15 13 12 15 15 8 10 14 8 12 15 13 12 14 13 10 13 11 12 15 10 9 9 20 17 19 26 15 12 12 15 16 8 10 14 8 13 15 14 12 14 14 11 13 13 12 15 10 11 10 20 18 20 26 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 24 10 6 6 6 6 31 6 11 6 6 6 19 6 6 6 6 16 17 6 9 6 6 6 6 6 6 S R R S S S R R S S R R R R R R R R R R R R R R R R S S R R S S R R R R R R R R R R R I R R R R S S R R S S R R R R R R R R R R R I R R R I S S S R R S S R R R R S S S R R S S S S S S S S S S R R S S R R R R R S R R R R R R I R R R S S S R R S S R R R R S S S S R S S S S R R S
Note: s: sensitivity I: an intermediate R: drug resistance
TABLE 2 Strain blank AB Fabric PNSM
20 times of no-washing of fabrics, 20 times of high-pressure no-washing and 20 times of high-pressure no-washing of 50 times of pseudomonas aeruginosa, 15131616 staphylococcus aureus, 15171515 escherichia coli, 13141815 MRSA, 14141715 bacillus cereus, 1113131515 vibrio vulnificus, 16161617 candida albicans, 21 11111111B group hemolytic streptococcus, 11111211 pseudomonas maltophilia, 12121514 nitrate negative bacillus, 14141315 salmonella paratyphi, 12, 12141914 salmonella alimentarius, 14141514 citrobacter, 14141513 pneumobacillus, 13131713 bacillus subtilis, 12121212 rhizogenes, 1012121212 alcaligenes faecalis, 14121616 pseudomonas stutzeri 12121413 Enterobacter cloacae-13131313 gonococcus-11111111
The results show that PNSM has inhibition effect on 20 strains of bacteria, and on bacteria which are easy to generate drug resistance, such as staphylococcus aureus drug-resistant strains (MRSA), pseudomonas aeruginosa, pseudomonas maltophilia, nitrate negative bacillus and the like, the inhibition effect on the bacteria is not obviously affected after high pressure and washing for 20 times and 50 times, and the bacteria cannot be inhibited after the AB fabric is washed for 20 times, so that the inhibition range of PNSM is wider than that of the AB fabric, and the inhibition effect cannot be affected by washing.

Claims (10)

1. The nano-silver gynecological disease antibacterial and anti-inflammatory membrane is characterized by containing pharmaceutically acceptable additives and anti-aggregation broad-spectrum antibacterial nano-silver micro powder, wherein the nano-silver has the particle size of 1-100 nanometers, the surface layer is silver oxide of 2-8 nanometers, the core is elemental silver, the thickness of the membrane is 10-100 micrometers, and the content of the nano-silver is 5-20 micrograms/cm2。
2. The nano-silver gynecological disease antibacterial and anti-inflammatory film according to claim 1, wherein the pharmaceutically acceptable additives comprise a monomer carrier, a surfactant, a disintegrant and a transdermal enhancer.
3. The nano-silver gynecological disease antibacterial and anti-inflammatory membrane as claimed in claims 1 and 2, characterized in that the medicament formula is (by weight of 10 kg of pure raw materials):
a: 3 to 4% of polyvinyl alcohol 17-88, 5 to 6% of PVA 25-99,
1 to 2 percent of starch sodium glycolate, 0.1 to 1 percent of nano-silver micro-powder aqueous solution,
0.2-0.5% sodium lauryl sulfate;
b: 8-10% of PVA17-99 aqueous solution;
c: 3-4% nitrocellulose solution.
4. The nano-silver gynecological disease antibacterial and anti-inflammatory membrane as claimed in claims 1 and 2, wherein the monomer carrier is a natural high molecular polymer membrane forming material or a synthetic high molecular polymer membrane forming material, preferably polyvinyl alcohol.
5. The nano-silver gynecological disease antibacterial and anti-inflammatory membrane according to claims 1 and 2, wherein the surfactant is an ionic surfactant and a nonionic surfactant, preferably sodium lauryl sulfate.
6. The nano-silver gynecological disease antibacterial and anti-inflammatory film according to claims 1 and 2, wherein the disintegrating agent is starch and starch derivatives, cellulose surfactants, effervescent mixtures and gums, preferably sodium starch glycolate.
7. The nano-silver gynecological disease antibacterial and anti-inflammatory membrane according to claims 1 and 2, wherein the transdermal enhancer is a natural or synthetic polymer and a synthetic elastomer, preferably nitrocellulose.
8. The industrial production process of the nano-silver gynecological disease antibacterial and anti-inflammatory membrane as claimed in claims 1 to 3, characterized by comprising the following steps of preparing the drug and the monomer carrier according to the following proportion:
the formula of the medicament is (based on 10 kilograms of the Chinese stub raw materials by weight):
a: 3 to 4% of polyvinyl alcohol 17-88, 5 to 6% of PVA 25-99,
1 to 2 percent of starch sodium glycolate, 0.1 to 1 percent of nano-silver micro-powder aqueous solution,
0.2-0.5% sodium lauryl sulfate;
b: 8-10% of PVA17-99 aqueous solution;
c: 3-4% nitrocellulose solution.
Then homogenizing, preparing auxiliary agent, coating film for one time, two times and three times, drying, cutting and the like.
9. The industrial production process of nano-silver gynecological disease antibacterial and anti-inflammatory membrane as claimed in claim 8, wherein the preparation of the medicament and the monomer carrier, homogenization, preparation of the adjuvant, three times of film coating in sequence of B, C, A under heating, and drying until the product is yellow brown yellow.
10. The application of the nano-silver gynecological disease antibacterial and anti-inflammatory membrane according to claims 1 to 3, which is characterized in that the membrane can be used for preventing and treating gynecological bacterial vaginitis, mycotic vaginitis and mixed infection vaginitis, and also can be used for preventing and treating gonorrhea and cervicitis.
CN01129505A 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process Pending CN1328819A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CNB011107677A CN1179646C (en) 2001-04-20 2001-04-20 Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process
CN01223000U CN2479952Y (en) 2001-04-20 2001-05-08 Nm silver plaster for trauma
CN01129505A CN1328819A (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process
CNB011295074A CN1169529C (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process
CNB018231578A CN1224479C (en) 2001-04-20 2001-11-26 Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application
PCT/CN2001/001584 WO2002090025A1 (en) 2001-04-20 2001-11-26 Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNB011107677A CN1179646C (en) 2001-04-20 2001-04-20 Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process
CN01223000U CN2479952Y (en) 2001-04-20 2001-05-08 Nm silver plaster for trauma
CN01129505A CN1328819A (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process
CNB011295074A CN1169529C (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process

Publications (1)

Publication Number Publication Date
CN1328819A true CN1328819A (en) 2002-01-02

Family

ID=27429906

Family Applications (5)

Application Number Title Priority Date Filing Date
CNB011107677A Expired - Fee Related CN1179646C (en) 2001-04-20 2001-04-20 Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process
CN01223000U Expired - Lifetime CN2479952Y (en) 2001-04-20 2001-05-08 Nm silver plaster for trauma
CNB011295074A Expired - Fee Related CN1169529C (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process
CN01129505A Pending CN1328819A (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process
CNB018231578A Expired - Fee Related CN1224479C (en) 2001-04-20 2001-11-26 Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CNB011107677A Expired - Fee Related CN1179646C (en) 2001-04-20 2001-04-20 Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process
CN01223000U Expired - Lifetime CN2479952Y (en) 2001-04-20 2001-05-08 Nm silver plaster for trauma
CNB011295074A Expired - Fee Related CN1169529C (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB018231578A Expired - Fee Related CN1224479C (en) 2001-04-20 2001-11-26 Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application

Country Status (2)

Country Link
CN (5) CN1179646C (en)
WO (1) WO2002090025A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6692773B2 (en) 2000-07-27 2004-02-17 Nucryst Pharmaceuticals Corp. Treatment of hyperproliferative skin disorders and diseases
US6719987B2 (en) 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
US6723350B2 (en) 2001-04-23 2004-04-20 Nucryst Pharmaceuticals Corp. Lubricious coatings for substrates
US6989157B2 (en) 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US7078060B2 (en) 2000-07-27 2006-07-18 Nucryst Pharmaceuticals Corp. Solutions and aerosols of metal-containing compounds
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US7201925B2 (en) 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases
US7255881B2 (en) 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
CN100396290C (en) * 2006-11-03 2008-06-25 段炬红 External use anti-bacteria foaming agent for gynecology
US7427416B2 (en) 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US7470437B2 (en) 2000-07-27 2008-12-30 Nucryst Pharmaceuticals Corp. Methods of treating conditions with a metal-containing material
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002315728A1 (en) * 2002-06-03 2003-12-19 Shenzhen Tsinghua Yuanxing Nano-Material Co., Ltd. Composite nanostuctured silver
DE10346387A1 (en) * 2003-10-07 2005-06-09 Henkel Kgaa Antimicrobial equipment of bathroom and toilet articles
EP1616926A1 (en) 2004-07-15 2006-01-18 Interuniversitair Microelektronica Centrum ( Imec) Slurry composition and method for chemical polishing of copper integrated with tungsten based barrier metals
US8399027B2 (en) 2005-04-14 2013-03-19 3M Innovative Properties Company Silver coatings and methods of manufacture
CN100386369C (en) * 2005-06-03 2008-05-07 陈汝霖 New type products of Nano silver latex, and preparation method
WO2007017901A2 (en) * 2005-06-08 2007-02-15 Khandelwal Sanjeev Silver nanoparticle dispersion formulation
US20070166399A1 (en) 2006-01-13 2007-07-19 3M Innovative Properties Company Silver-containing antimicrobial articles and methods of manufacture
EP2029148A2 (en) * 2006-06-16 2009-03-04 Merck Patent GmbH Antimicrobial carbon
CN100457084C (en) * 2006-08-04 2009-02-04 武汉正午阳光医药生物科技有限公司 Nanometer silver type external use antibiotic gel for female external use and its prepn. method
CN101049279B (en) * 2007-04-30 2010-06-23 东莞市拓扑光电科技有限公司 Antibacterial shampoo of Nano silver, and preparation method
US8815307B2 (en) * 2008-12-31 2014-08-26 Colotex Industrial Co., Ltd. Process for producing porous polymer masterbatch and fiber thereof having anti-bacterial and odor eliminating functions
CN102430761A (en) * 2011-12-12 2012-05-02 池州学院 Preparation method for water-soluble nano silver for killing oncomelania hupensis
CN103341642B (en) * 2013-07-26 2015-12-02 莆田学院 A kind of cellulose green syt method of nano silver particles
CN103688996B (en) * 2013-11-28 2014-12-10 太原理工大学 Method for preparing silver-loaded antibacterial agent by using waste cotton fiber
CN105640986A (en) * 2014-11-28 2016-06-08 广东工业大学 Silver nanoparticle composition for control of lung cancer and prostate cancer
CN107598186B (en) * 2017-08-30 2019-08-20 苏州工业园区格云环保新材料有限公司 A kind of preparation method of nano silver and its fumigation liquid
CN109137490A (en) * 2018-06-27 2019-01-04 苏州市天翱特种织绣有限公司 A kind of antibacterial modified method of cotton fiber
EP3920726B1 (en) * 2019-02-05 2024-11-13 Griffith Foods International Inc. Anti-caking agent or flow agent for a seasoning, pharmaceuticals or nutraceuticals
CN111763365B (en) * 2020-07-17 2022-09-02 安信纳米生物科技（珠海）有限公司 Antibacterial fresh-keeping material containing nano-silver and preparation method thereof
CN113664213B (en) * 2021-08-04 2023-11-21 湖南伟方生命科技有限公司 Preparation method and application of nano silver antibacterial liquid
CN114028318B (en) * 2021-10-14 2023-11-21 湖南伟方生命科技有限公司 Male antibacterial liquid and preparation method and application thereof
CN115137681A (en) * 2022-06-23 2022-10-04 深圳市黄田荔枝品牌发展有限公司 Litchi mask and preparation method thereof
CN117206515A (en) * 2023-01-06 2023-12-12 苏州星翰新材料科技有限公司 A method for preparing low-temperature sintering submicron nanoscale silver powder
CN116511521A (en) * 2023-05-04 2023-08-01 贵州华星冶金有限公司 Silver powder preparation method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07173022A (en) * 1993-12-17 1995-07-11 Asahi Chem Ind Co Ltd Antimicrobial agent
CN1058868C (en) * 1994-11-26 2000-11-29 广州安信生物科技发展有限公司 Long-effect and broad-spectrum antibiotic granules and its production
JP4025839B2 (en) * 1996-09-12 2007-12-26 Ｄｏｗａエレクトロニクス株式会社 Silver powder and method for producing silver powder
CN1161511C (en) * 1999-07-27 2004-08-11 蒋建华 Long-acting wide-spectrum antiseptic nanometer silver fabric and its making method
CN1266761A (en) * 2000-03-23 2000-09-20 南京大学 Process for preparing nm-class silver powder

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US6719987B2 (en) 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
US7078060B2 (en) 2000-07-27 2006-07-18 Nucryst Pharmaceuticals Corp. Solutions and aerosols of metal-containing compounds
US6692773B2 (en) 2000-07-27 2004-02-17 Nucryst Pharmaceuticals Corp. Treatment of hyperproliferative skin disorders and diseases
US6989157B2 (en) 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
US7470437B2 (en) 2000-07-27 2008-12-30 Nucryst Pharmaceuticals Corp. Methods of treating conditions with a metal-containing material
US7427416B2 (en) 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US7255881B2 (en) 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US7087249B2 (en) 2001-04-23 2006-08-08 Nucryst Pharmaceuticals Corp. Treatment of mucosal membranes
US6723350B2 (en) 2001-04-23 2004-04-20 Nucryst Pharmaceuticals Corp. Lubricious coatings for substrates
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US6939568B2 (en) 2001-04-23 2005-09-06 Nucryst Pharmaceuticals Corp. Treatment of inflammatory skin conditions
US6989156B2 (en) 2001-04-23 2006-01-24 Nucryst Pharmaceuticals Corp. Therapeutic treatments using the direct application of antimicrobial metal compositions
US7201925B2 (en) 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases
CN100396290C (en) * 2006-11-03 2008-06-25 段炬红 External use anti-bacteria foaming agent for gynecology
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof

Also Published As

Publication number Publication date
CN1322474A (en) 2001-11-21
CN1179646C (en) 2004-12-15
CN1505551A (en) 2004-06-16
CN1328827A (en) 2002-01-02
CN2479952Y (en) 2002-03-06
WO2002090025A1 (en) 2002-11-14
CN1224479C (en) 2005-10-26
CN1169529C (en) 2004-10-06

Similar Documents

Publication Publication Date Title
CN1328819A (en) Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process
Ran et al. Hyaluronic acid-templated Ag nanoparticles/graphene oxide composites for synergistic therapy of bacteria infection
CN101999412B (en) Nano-silver solution and preparation method thereof
US20030185889A1 (en) Colloidal nanosilver solution and method for making the same
CN1161511C (en) Long-acting wide-spectrum antiseptic nanometer silver fabric and its making method
CN1147640C (en) Antibacterial fabric containing nm-class silver powder and its making method
CN111802404B (en) Nano silver composite antibacterial and sterilizing material
CN1183285C (en) Aggregation-preventing wide-spectrum nanometer antibiotic silver yarn and its industrial production process
CN1291667A (en) Nanometer silver anti-bacteria cloth and its industrial production technology
CN115785475B (en) Antibacterial metal organic framework material and preparation method and application thereof
He et al. One-pot synthesis of chlorhexidine-templated biodegradable mesoporous organosilica nanoantiseptics
Cai et al. Sericin-assisted green synthesis of gold nanoparticles as broad-spectrum antimicrobial and biofilm-disrupting agents for therapy of bacterial infection
CN1369206A (en) Nano Silver sterilizing gel, its preparing method and use
CN115671266A (en) A gallium ion and enzyme co-loaded antibacterial agent and its preparation method and application
CN107568265B (en) Silver-rare earth composite antibacterial agent for plastics
CN111803695B (en) Preparation method of NO release type wound dressing based on silver-doped carbon dots, product and application thereof
CN1156624C (en) Aggregation-preventing wide-spectrum antiseptic nanometer silver knitted article and fabric and their industrial production process
CN111820240A (en) Antibacterial and disinfectant additive based on nano metal wires and preparation method thereof
CN115671280B (en) A copper-source heterojunction nano antibacterial agent and its preparation method and application
CN103110572B (en) Gynecological antimicrobial gel recipe and preparation method thereof
CN113244267B (en) A kind of red algae polysaccharide nano silver and its antibacterial gel prepared and application
CN1685828A (en) Silver-zinc particle nano pore composite material and its application in surface anti infection region
Ghosh et al. pH-Triggered in-situ release of silver nanoparticle in hydrogel for topical applications
CN112168809A (en) Novel nano-silver antibacterial material and preparation method and application thereof
CN1206990C (en) Liquid preparation containing norfloxacin and metronidazole

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication